Evidence map›Paper›PMID 33617940›Full record

ReviewRegulatory toxicology and pharmacology : RTP2021

Regulatory landscape of nanotechnology and nanoplastics from a global perspective.

Jacqueline Allan, Susanne Belz, Arnd Hoeveler, Marta Hugas, Haruhiro Okuda, Anil Patri, Hubert Rauscher, Primal Silva, William Slikker, Birgit Sokull-Kluettgen and 2 more

Abstract readReview
In one paragraph

Review in Regulatory toxicology and pharmacology : RTP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jacqueline AllanJoint Institute for Innovation Policy, Belgium.
Susanne BelzEuropean Commission, Joint Research Centre (JRC), Italy.
Arnd HoevelerEuropean Commission, Joint Research Centre (JRC), Italy.
Marta HugasEuropean Food Safety Authority (EFSA), Italy.
Haruhiro OkudaNational Institute of Health Sciences (NIHS), Japan.
Anil PatriNational Center for Toxicological Research (NCTR), Food and Drug Administration (FDA), USA.
Hubert RauscherEuropean Commission, Joint Research Centre (JRC), Italy.
Primal SilvaCanadian Food Inspection Agency, Canada.
William SlikkerNational Center for Toxicological Research (NCTR), Food and Drug Administration (FDA), USA.
Birgit Sokull-KluettgenEuropean Commission, Joint Research Centre (JRC), Italy.
Weida TongNational Center for Toxicological Research (NCTR), Food and Drug Administration (FDA), USA.
Elke AnklamEuropean Commission, Joint Research Centre (JRC), Belgium. Electronic address: elke.anklam@ec.europa.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology and more particularly nanotechnology-based products and materials have provided a huge potential for novel solutions to many of the current challenges society is facing. However, nanotechnology is also an area of product innovation that is sometimes developing faster than regulatory frameworks. This is due to the high complexity of some nanomaterials, the lack of a globally harmonised regulatory definition and the different scopes of regulation at a global level. Research organisations and regulatory bodies have spent many efforts in the last two decades to cope with these challenges. Although there has been a significant advancement related to analytical approaches for labelling purposes as well as to the development of suitable test guidelines for nanomaterials and their safety assessment, there is a still a need for greater global collaboration and consensus in the regulatory field. Furthermore, with growing societal concerns on plastic litter and tiny debris produced by degradation of littered plastic objects, the impact of micro- and nanoplastics on humans and the environment is an emerging issue. Despite increasing research and initial regulatory discussions on micro- and nanoplastics, there are still knowledge gaps and thus an urgent need for action. As nanoplastics can be classified as a specific type of incidental nanomaterials, current and future scientific investigations should take into account the existing profound knowledge on nanotechnology/nanomaterials when discussing issues around nanoplastics. This review was conceived at the 2019 Global Summit on Regulatory Sciences that took place in Stresa, Italy, on 24-26 September 2019 (GSRS 2019) and which was co-organised by the Global Coalition for Regulatory Science Research (GCRSR) and the European Commission's (EC) Joint Research Centre (JRC). The GCRSR consists of regulatory bodies from various countries around the globe including EU bodies. The 2019 Global Summit provided an excellent platform to exchange the latest information on activities carried out by regulatory bodies with a focus on the application of nanotechnology in the agriculture/food sector, on nanoplastics and on nanomedicines, including taking stock and promoting further collaboration. Recently, the topic of micro- and nanoplastics has become a new focus of the GCRSR. Besides discussing the challenges and needs, some future directions on how new tools and methodologies can improve the regulatory science were elaborated by summarising a significant portion of discussions during the summit. It has been revealed that there are still some uncertainties and knowledge gaps with regard to physicochemical properties, environmental behaviour and toxicological effects, especially as testing described in the dossiers is often done early in the product development process, and the material in the final product may behave differently. The harmonisation of methodologies for quantification and risk assessment of nanomaterials and micro/nanoplastics, the documentation of regulatory science studies and the need for sharing databases were highlighted as important aspects to look at.

Indexed as

InternationalityEnvironmental ExposureEnvironmental HealthMicroplasticsNanostructuresReference StandardsMicroplasticsGSRSHarmonisationNanomaterialsNanoplasticsNanotechnologyRegulatory scienceStandards

Identifiers

PMID33617940
PMCPMC8121750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.